SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Butterfly Network, Inc. designs a medical imaging device that reduces the cost of real-time and three-dimensional imaging and treatment. It develops and provides a whole-body portable ultrasound scanner called the iQ Device and related hosted, web-based application, application programming interfaces and platform services, which the firm offer to physicians or other licensed health care providers. Its products include iQ+ Ultrasound, Butterfly Enterprise and iQ Vet. The company was founded by Jonathan M. Rothberg on January 25, 2011 and is headquartered in Burlington, MA.

Butterfly Network Inc - Ordinary Shares - Class A

Butterfly Network Inc

Butterfly Network is surging following record quarterly revenue and the milestone achievement of positive operating cash flow, signaling a significant transition toward profitability. Investors are actively discussing the company's shift from a pure medical device firm to a semiconductor-based AI imaging platform, with many weighing the impact of its strategic partnership with Midjourney against historical skepticism regarding share offerings and long-term cash burn.

Strategy, Inc. engages in the development of fixed-income instruments that provide investors varying degrees of economic exposure to bitcoin. It executes bitcoin acquisition, capital management, and capital markets strategies. The company was founded by Michael J. Saylor and Sanjeev K. Bansal on November 17, 1989, and is headquartered in Tysons Corner, VA.

Strategy Inc. - Ordinary Shares - Class A

Strategy

MicroStrategy is facing intense bearish sentiment and significant volatility as community members aggressively debate the sustainability of its debt-driven Bitcoin acquisition strategy and recent stock dilution. Investors remain deeply divided, with some highlighting the company's leverage as a potential systemic risk, while others view the current price compression as a long-term accumulation opportunity despite the ongoing downward pressure.

Ardelyx, Inc. is a commercial-stage biopharmaceutical company focused on the development and commercialization of innovative medicines that meet significant unmet medical needs. Its products include IBSRELA and XPHOZAH. The company was founded by Dominique Charmot, Peter G. Schultz, and Jean M. Frechet in October 2007 and is headquartered in Waltham, MA.

Ardelyx Inc

Ardelyx is attracting significant community attention due to strong IBSRELA revenue growth and speculation regarding a potential acquisition by Zydus Lifesciences. Investors are closely monitoring the stock's price action as they balance this momentum against the uncertainty surrounding the ongoing legal dispute with CMS.

Energy Fuels, Inc. is a mining development company, which engages in the exploration and evaluation of uranium and vanadium properties. It operates through the following segments: Uranium, Rare Earth Elements (REE), and Heavy Mineral Sands (HMS). The uranium segment engages in conventional and ISR uranium extraction, recovery and sales of uranium from mineral properties and the recycling of uranium-bearing materials generated by third parties along with the exploration, permitting and evaluation of uranium properties in the U.S. The REE segment is engaged in the company’s initiatives to progress towards full REE separation capabilities at the Mill to produce both light and heavy separated REE oxides in the coming years. The HMS segment engages in the exploration, development and recovery of HMS at the Kwale Project, Bahia Project, Vara Mada Project and the company’s equity method investments in the Donald Project JV and Tate. The company was founded by George E. L. Glasier and John David Mason on June 24, 1987 and is headquartered in Lakewood, CO.

Energy Fuels Inc

Energy Fuels is trending as investors focus on the company's strategic position at the intersection of nuclear energy and domestic rare earth supply chains, bolstered by recent government financial support and a push toward independence from foreign critical mineral sources. Community discussion centers on the potential for long-term growth driven by AI-linked power demand, while some investors urge patience as the company executes its mill retooling and finalizes key strategic partnerships.

Sezzle, Inc. engages in the operation of a digital payment platform that enables bank-to-bank transfer of money between consumers and businesses. The company was founded by Charlie G. Youakim, Killian Brackey and Paul V. Paradis on January 4, 2016 and is headquartered in Minneapolis, MN.

Sezzle Inc.

Sezzle is seeing intense community debate as investors weigh strong earnings momentum and institutional accumulation against concerns regarding governance, legal investigations, and the broader volatility impacting the fintech sector. The conversation remains highly polarized, with many bulls anticipating a violent short squeeze driven by heavy short interest and positive product expansion, while others focus on technical pullbacks and the risks of a shifting macroeconomic landscape.

Avalanche is a high throughput smart contract blockchain&nbsp;platform. Validators secure the network through a proof-of-stake consensus protocol. It is said to be fast, low cost, and environmental friendly.

Avalanche

Avalanche is facing intense selling pressure and retail frustration as the token struggles to maintain support levels, with investors debating whether current price points represent an accumulation opportunity or the bottom of a broader downward trend. Community discussion is heavily focused on the token's lackluster performance compared to other assets, concerns over its long-term viability, and widespread skepticism regarding the impact of upcoming regulatory developments.

A composable native asset bridge with unified liquidity and instant guaranteed finality

Stargate

Stargate is gaining attention as community members track its price action and potential recovery from recent volatility. Discussions are heavily focused on the project's role in the DeFi ecosystem, with some investors debating entry points while others analyze its long-term utility and bridge infrastructure.

Cerebras Systems, Inc. engages in the designing and provision of processors for artificial intelligence (AI) training and inference. Its products include inference, Wafer Scale Engine, AI supercomputers, AI model services, cloud, systems, and processors. The company was founded by Sean Lie, Andrew D. Feldman, Gary Lauterbach, Michael James, and Jean Philippe Fricker in 2015 and is headquartered in Sunnyvale, CA.

Cerebras Systems Inc - Ordinary Shares - Class A

Cerebras Systems Inc

Cerebras Systems is capturing investor attention as the community debates its high-speed AI inference capabilities compared to traditional GPU architectures, with active discussion surrounding upcoming earnings and the potential for new contract announcements. While bulls highlight its strategic growth in the agentic AI market, bears remain cautious about the stock's valuation, insider lock-up periods, and intense competition within the semiconductor space.

Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products include diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly on May 10, 1876 and is headquartered in Indianapolis, IN.

Lilly(Eli) & Co

Eli Lilly is trending as investors respond to a series of positive clinical trial results for its next-generation obesity treatment, retatrutide, alongside news of expanded insurance coverage for its core GLP-1 portfolio. The community is actively debating the company's long-term pipeline dominance and its strategic shift into broader therapeutic areas, including infectious disease and oncology, while tracking its momentum toward new record highs.

Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care and Rare Disease segments. The Diabetes and Obesity Care segment includes diabetes, obesity, cardiovascular, and emerging therapy areas. The Rare Disease segment refers to rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1923 is headquartered in Bagsværd, Denmark.

Novo Nordisk - ADR

Novo Nordisk A/S

Novo Nordisk is currently drawing significant attention as investors monitor the strong launch momentum of its Wegovy oral pill and navigate heightened competitive pressure from Eli Lilly in the GLP-1 market. The community is actively debating the stock's long-term value against its recent underperformance, with many focusing on whether expanding global access and pipeline developments can overcome concerns over pricing competition and pipeline execution.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Neutral Sentiment

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Current Price	N/A
Prev Close	N/A
Open	N/A
Dividend Yield	N/A
50-Day Moving Average	N/A
Beta	N/A
Avg. Volume	N/A
PE Ratio	N/A

52-Week High	N/A
52-Week Low	N/A
Market Capitalization	N/A
EPS (Annual)	N/A
Price to Book	N/A
Revenue Per Employee	N/A

LSMCFLyxor Asset Management Luxembourg S.A. - Amundi MSCI Semiconductors - UCITS ETF Acc

Feed

News

Sentiment

Fundamentals

Info

Latest LSMCF News